{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:39:21Z","timestamp":1792215561240,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81672971"],"award-info":[{"award-number":["81672971"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2017YFC0113201"],"award-info":[{"award-number":["2017YFC0113201"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>We investigated the risk factors of radiation-induced thyroid dysfunction, then combined the clinical factors and optimum thyroid dosimetric parameters to predict the incidence rate of hypothyroidism (HT) and to guide individualized treatment.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A total of 206 patients with histologically proven nasopharyngeal carcinoma (NPC) treated at the Cancer Hospital of the University of Chinese Academy of Sciences between January 2015 and August 2018 were included. Dose\u2013volume histogram (DVH) data, including mean dose, absolute volume, V<jats:sub>20<\/jats:sub>, V<jats:sub>25<\/jats:sub>, V<jats:sub>30<\/jats:sub>, V<jats:sub>35<\/jats:sub>, V<jats:sub>40<\/jats:sub>, V<jats:sub>45<\/jats:sub>, V<jats:sub>50,<\/jats:sub> V<jats:sub>55<\/jats:sub>, and V<jats:sub>60<\/jats:sub> were extracted and used as dosimetric parameters. A logistic regression analysis model was built to identify predictors related to HT occurring within 2\u2009years.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Sex, N stage, thyroid volume, mean thyroid dose, and thyroid V<jats:sub>20<\/jats:sub> and V<jats:sub>50<\/jats:sub> were significantly different between patients with and without HT. Logistic regression analysis showed that N stage, thyroid volume, and thyroid V<jats:sub>50<\/jats:sub> were independent predictors of HT. The radiosensitivity of the thyroid decreased as the thyroid volume increased. Patients with N stage &gt;\u20091 had significantly higher HT incidence (37.38%) than patients with N stage \u22641 (13.11%). The incidence of HT was 54.55% in patients with thyroid V<jats:sub>50<\/jats:sub> &gt; 24% and was 34.15% in patients with thyroid V<jats:sub>50<\/jats:sub>\u2009\u2264\u200924%.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The incidence of HT is significantly associated with N stage, thyroid volume, and thyroid V<jats:sub>50<\/jats:sub>. More attention should be paid to patients with NPC with thyroid volume\u2009\u2264\u200912.82\u2009cm<jats:sup>3<\/jats:sup> and advanced N stage disease.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13014-020-01490-x","type":"journal-article","created":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T10:02:32Z","timestamp":1584957752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Thyroid V50 is a risk factor for hypothyroidism in patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy: a retrospective study"],"prefix":"10.1186","volume":"15","author":[{"given":"Ling","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Lu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Juan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Hua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,23]]},"reference":[{"key":"1490_CR1","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2003.06.158","volume":"15","author":"JC Lin","year":"2003","unstructured":"Lin JC, Jan JS, Hsu CY, et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003;15:631\u20137.","journal-title":"J Clin Oncol"},{"key":"1490_CR2","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/cncr.31031","volume":"124","author":"WB Huang","year":"2018","unstructured":"Huang WB, Chan JYW, Liu DL, et al. Human papillomavirus and World Health Organization type III nasopharyngeal carcinoma: multicenter study from an endemic area in southern China. Cancer. 2018;124:530\u20136.","journal-title":"Cancer"},{"key":"1490_CR3","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/jama.1976.03270150025024","volume":"236","author":"MB Rosenthal","year":"1976","unstructured":"Rosenthal MB, Goldfine ID. Primary and secondary hypothyroidism in nasopharyngeal carcinoma. JAMA. 1976;236:1591\u20133.","journal-title":"JAMA"},{"key":"1490_CR4","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/hed.24150","volume":"38","author":"TL Huang","year":"2016","unstructured":"Huang TL, Chien CY, Tsai WL, et al. Long-term late toxicities and quality of life for survivors of nasopharyngeal carcinoma treated with intensity-modulated radiotherapy versus non-intensity-modulated radiotherapy. Head Neck. 2016;38:1026\u201332.","journal-title":"Head Neck."},{"key":"1490_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ijrobp.2012.09.033","volume":"85","author":"H Yang","year":"2013","unstructured":"Yang H, Hu W, Wang W, et al. Replanning during intensity modulated radiation therapy improved quality of life in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2013;85:47\u201354.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1490_CR6","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1002\/cncr.25773","volume":"117","author":"YY Chen","year":"2011","unstructured":"Chen YY, Zhao C, Wang J, et al. Intensity-modulated radiation therapy reduces radiation-induced trismus in patients with nasopharyngeal carcinoma: a prospective study with >5 years of follow-up. Cancer. 2011;117:2910\u20136.","journal-title":"Cancer"},{"key":"1490_CR7","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1002\/hed.23482","volume":"36","author":"V Murthy","year":"2014","unstructured":"Murthy V, Narang K, Ghosh-Laskar S, et al. Hypothyroidism after 3-dimensional conformal radiotherapy and intensity-modulated radiotherapy for head and neck cancers: prospective data from 2 randomized controlled trials. Head Neck. 2014;36:1573\u201380.","journal-title":"Head Neck"},{"key":"1490_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.clon.2016.05.004","volume":"28","author":"V Lee","year":"2016","unstructured":"Lee V, Chan SY, Choi CW, et al. Dosimetric predictors of hypothyroidism after radical intensity-modulated radiation therapy for non-metastatic nasopharyngeal carcinoma. Clin Oncol. 2016;28:52\u201360.","journal-title":"Clin Oncol"},{"key":"1490_CR9","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ijrobp.2018.05.060","volume":"102","author":"LJ McDowell","year":"2018","unstructured":"McDowell LJ, Rock K, Xu W, et al. Long-term late toxicity, quality of life, and emotional distress in patients with nasopharyngeal carcinoma treated with intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2018;102:340\u201352.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1490_CR10","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1093\/jrr\/rry036","volume":"59","author":"C Lertbutsayanukul","year":"2018","unstructured":"Lertbutsayanukul C, Kitpanit S, Prayongrat A, et al. Validation of previously reported predictors for radiation-induced hypothyroidism in nasopharyngeal cancer patients treated with intensity-modulated radiation therapy, a post hoc analysis from a phase III randomized trial [J]. J Radiat Res. 2018;59:446\u201355.","journal-title":"J Radiat Res"},{"key":"1490_CR11","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.clon.2018.07.002","volume":"30","author":"VM Patil","year":"2018","unstructured":"Patil VM, Noronha V, Joshi A, et al. Influence of hypothyroidism after Chemoradiation on outcomes in head and neck Cancer. Clin Oncol. 2018;30:675.","journal-title":"Clin Oncol"},{"key":"1490_CR12","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/S0140-6736(17)30703-1","volume":"390","author":"L Chaker","year":"2017","unstructured":"Chaker L, Bianco AC, Jonklaas J, et al. Hypothyroidism. Lancet. 2017;390:1550\u201362.","journal-title":"Lancet"},{"key":"1490_CR13","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1001\/jama.2010.1361","volume":"304","author":"N Rodondi","year":"2010","unstructured":"Rodondi N, den Elzen WP, Bauer DC, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010;304:1365\u201374.","journal-title":"JAMA"},{"key":"1490_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2011.03.002","volume":"99","author":"MJ Boomsma","year":"2011","unstructured":"Boomsma MJ, Bijl HP, Langendijk JA. Radiation-induced hypothyroidism in head and neck cancer patients: a systematic review. Radiother Oncol. 2011;99:1\u20135.","journal-title":"Radiother Oncol"},{"key":"1490_CR15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S1470-2045(11)70303-5","volume":"13","author":"NY Lee","year":"2012","unstructured":"Lee NY, Zhang Q, Pfister DG, et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol. 2012;13:172\u201380.","journal-title":"Lancet Oncol"},{"key":"1490_CR16","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.radonc.2017.04.025","volume":"123","author":"CY Fan","year":"2017","unstructured":"Fan CY, Lin CS, Chao HL, et al. Risk of hypothyroidism among patients with nasopharyngeal carcinoma treated with radiation therapy: a population-based cohort study. Radiother Oncol. 2017;123:394\u2013400.","journal-title":"Radiother Oncol"},{"key":"1490_CR17","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.ijrobp.2009.03.011","volume":"76","author":"YH Wu","year":"2010","unstructured":"Wu YH, Wang HM, Chen HH, et al. Hypothyroidism after radiotherapy for nasopharyngeal cancer patients. Int J Radiat Oncol Biol Phys. 2010;76:1133\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1490_CR18","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1007\/s12032-013-0710-9","volume":"30","author":"S Huang","year":"2013","unstructured":"Huang S, Wang X, Hu C, et al. Hypothalamic-pituitary-thyroid dysfunction induced by intensity-modulated radiotherapy (IMRT) for adult patients with nasopharyngeal carcinoma. Med Oncol. 2013;30:710.","journal-title":"Med Oncol"},{"key":"1490_CR19","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ijrobp.2006.08.051","volume":"67","author":"D Alterio","year":"2007","unstructured":"Alterio D, Jereczek-Fossa BA, Franchi B, et al. Thyroid disorders in patients treated with radiotherapy for head-and-neck cancer: a retrospective analysis of seventy-three patients. Int J Radiat Oncol Biol Phys. 2007;67:144\u201350.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1490_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ijrobp.2012.05.020","volume":"84","author":"MJ Boomsma","year":"2012","unstructured":"Boomsma MJ, Bijl HP, Christianen ME, et al. A prospective cohort study on radiation-induced hypothyroidism: development of an NTCP model. Int J Radiat Oncol Biol Phys. 2012;84:351\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1490_CR21","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1259\/bjr.20160686","volume":"90","author":"R Luo","year":"2017","unstructured":"Luo R, Li M, Yang Z, et al. Nomogram for radiation-induced hypothyroidism prediction in nasopharyngeal carcinoma after treatment. Br J Radiol. 2017;90:1070.","journal-title":"Br J Radiol"},{"key":"1490_CR22","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.ijrobp.2017.03.007","volume":"98","author":"K Sommat","year":"2017","unstructured":"Sommat K, Ong WS, Hussain A, et al. Thyroid V40 predicts primary hypothyroidism after intensity modulated radiation therapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2017;98:574\u201380.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1490_CR23","doi-asserted-by":"publisher","first-page":"488","DOI":"10.2478\/raon-2019-0055","volume":"53","author":"M Prpic","year":"2019","unstructured":"Prpic M, Kruljac I, Kust D, et al. Dose-volume derived Nomogram as a reliable predictor of radiotherapy-induced hypothyroidism in head and neck Cancer patients. Radiol Oncol. 2019;53:488\u201396.","journal-title":"Radiol Oncol"},{"key":"1490_CR24","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/hed.24643","volume":"39","author":"S Ling","year":"2017","unstructured":"Ling S, Bhatt AD, Brown NV, et al. Correlative study of dose to thyroid and incidence of subsequent dysfunction after head and neck radiation. Head Neck. 2017;39:548\u201354.","journal-title":"Head Neck."},{"key":"1490_CR25","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/COC.0000000000000165","volume":"40","author":"S Sachdev","year":"2017","unstructured":"Sachdev S, Refaat T, Bacchus ID, et al. Thyroid V50 highly predictive of hypothyroidism in head-and-neck Cancer patients treated with intensity-modulated radiotherapy (IMRT). Am J Clin Oncol. 2017;40:413\u20137.","journal-title":"Am J Clin Oncol"},{"key":"1490_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.oraloncology.2017.03.005","volume":"68","author":"RP Zhai","year":"2017","unstructured":"Zhai RP, Kong FF, Du CR, et al. Radiation-induced hypothyroidism after IMRT for nasopharyngeal carcinoma: clinical and dosimetric predictors in a prospective cohort study. Oral Oncol. 2017;68:44\u20139.","journal-title":"Oral Oncol"},{"key":"1490_CR27","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/1754-9485.12074","volume":"57","author":"Z Lin","year":"2013","unstructured":"Lin Z, Wang X, Xie W, et al. Evaluation of clinical hypothyroidism risk due to irradiation of thyroid and pituitary glands in radiotherapy of nasopharyngeal cancer patients. J Med Imaging Radiat Oncol. 2013;57:713\u20138.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"1490_CR28","first-page":"6126","volume":"16","author":"Y Xu","year":"2018","unstructured":"Xu Y, Shao Z, Tang T, et al. A dosimetric study on radiation-induced hypothyroidism following intensity-modulated radiotherapy in patients with nasopharyngeal carcinoma. Oncol Lett. 2018;16:6126\u201332.","journal-title":"Oncol Lett"},{"key":"1490_CR29","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1186\/s12885-018-4348-z","volume":"18","author":"R Luo","year":"2018","unstructured":"Luo R, Wu VWC, He B, et al. Development of a normal tissue complication probability (NTCP) model for radiation-induced hypothyroidism in nasopharyngeal carcinoma patients. BMC Cancer. 2018;18:575.","journal-title":"BMC Cancer"},{"key":"1490_CR30","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.ijrobp.2007.01.029","volume":"68","author":"N Bhandare","year":"2007","unstructured":"Bhandare N, Kennedy L, Malyapa RS, et al. Primary and central hypothyroidism after radiotherapy for head-and-neck tumors. Int J Radiat Oncol Biol Phys. 2007;68:1131\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-020-01490-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13014-020-01490-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-020-01490-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:17:13Z","timestamp":1616458633000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-020-01490-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,23]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1490"],"URL":"https:\/\/doi.org\/10.1186\/s13014-020-01490-x","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,23]]},"assertion":[{"value":"4 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The name of the ethics committee: Medical Ethics Committee of Zhejiang Cancer Hospital.The committee\u2019s reference number: IRB-2019-87.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}